CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
NCT ID: NCT02319486
Last Updated: 2015-03-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
26 participants
INTERVENTIONAL
2009-01-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topotecan Episcleral Plaque for Treatment of Retinoblastoma
NCT04428879
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
NCT04681417
A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma
NCT01466855
Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma
NCT00889018
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
NCT07188311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CEV with/without carboplatin
CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
carboplatin periocular injection
chemotherapy together with/without 20mg/2ml carboplatin periocular injection
CEV chemotherapy
vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carboplatin periocular injection
chemotherapy together with/without 20mg/2ml carboplatin periocular injection
CEV chemotherapy
vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* for patients with IRSS stage II disease, if scleral surface invasion alone was observed, only systemic chemotherapy was administered, whereas other IRSS stage II and IIIa patients received systemic chemotherapy plus additional local chemotherapy.
* no tumor-related treatment was given prior to this chemotherapy regimen.
Exclusion Criteria
* the diagnosis of IRSS stage I or above in the non-target eye.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Huasheng Yang
Huasheng Yang
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huasheng Yang, M.D, PHD
Role: STUDY_CHAIR
Zhongshan Ophthalmic Center, Sun Yat-sen University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
yanghs04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.